Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Lampson

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|August 3, 2019
For CLL cells, there's no place like homeBenjamin L Lampson, Jennifer R Brown
Blood|October 13, 2018
A new triple threat to CLLBenjamin L Lampson, Matthew S Davids
Hematology/Oncology Clinics of North America|June 27, 2021
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Jennifer R Brown
Current Hematologic Malignancy Reports|January 25, 2017
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Matthew S Davids
Expert Opinion on Investigational Drugs|September 26, 2017
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphomaBenjamin L Lampson, Jennifer R Brown
Expert Review of Hematology|January 31, 2018
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Benjamin L Lampson, Jennifer R Brown
The New England Journal of Medicine|September 1, 2016
CLINICAL PROBLEM-SOLVING. Tip of the TongueBenjamin L Lampson, Stacy W Gray, Edmund S Cibas, et al.
Plos One|October 10, 2015
Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic CancerJamie D Weyandt, Benjamin L Lampson, Sherry Tang, et al.
The Journal of Clinical Investigation|December 2, 2014
Rare codons capacitate Kras-driven de novo tumorigenesisNicole L K Pershing, Benjamin L Lampson, Jason A Belsky, et al.
Heartrhythm Case Reports|July 1, 2021
High-grade heart block associated with ibrutinib therapyAlexander R Vartanov, Benjamin L Lampson, Eric D Jacobsen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|August 3, 2019
For CLL cells, there's no place like homeBenjamin L Lampson, Jennifer R Brown
Blood|October 13, 2018
A new triple threat to CLLBenjamin L Lampson, Matthew S Davids
Hematology/Oncology Clinics of North America|June 27, 2021
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Jennifer R Brown
Current Hematologic Malignancy Reports|January 25, 2017
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Matthew S Davids
Expert Opinion on Investigational Drugs|September 26, 2017
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphomaBenjamin L Lampson, Jennifer R Brown
Expert Review of Hematology|January 31, 2018
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Benjamin L Lampson, Jennifer R Brown
The New England Journal of Medicine|September 1, 2016
CLINICAL PROBLEM-SOLVING. Tip of the TongueBenjamin L Lampson, Stacy W Gray, Edmund S Cibas, et al.
Plos One|October 10, 2015
Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic CancerJamie D Weyandt, Benjamin L Lampson, Sherry Tang, et al.
The Journal of Clinical Investigation|December 2, 2014
Rare codons capacitate Kras-driven de novo tumorigenesisNicole L K Pershing, Benjamin L Lampson, Jason A Belsky, et al.
Heartrhythm Case Reports|July 1, 2021
High-grade heart block associated with ibrutinib therapyAlexander R Vartanov, Benjamin L Lampson, Eric D Jacobsen, et al.
Pageof 3